Heron Therapeutics Inc HRTX

Company navigates mixed Q2 results with strong APONVIE growth, while withdrawing guidance due to CINVANTI patent challenges and exploring strategic alternatives.

Heron Therapeutics reported modest second-quarter revenue growth, but uncertainty around potential generic CINVANTI competition and a strategic alternatives process prompted the company to withdraw its full-year 2026 guidance. Key Investor TakeawaysHeron Therapeutics (NASDAQ:HRTX) reported Q2 2026 total net revenue of $37.

CARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 10, 2026, at 8:30 a.m. ET to report second quarter financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in deta

BV, RAIL and HRTX have been added to the Zacks Rank #5 (Strong Sell) List on July 15th, 2026.

Heron Therapeutics is back in focus after analysts trimmed their fair value price target from US$3.00 to US$2.00 per share, a reset that puts the current debate around the company’s outlook front and center. Much of this shift tracks recent Street commentary following the Cinvanti patent decision, with analysts reassessing downside risk from potential generic competition against any upside from an appeal and execution on the existing portfolio. As you read on, you will see how these changing...

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Heron Therapeutics, Inc. (NASDAQ:HRTX) is one of the most promising stocks on our list. TheFly reported on June 3 that H.C. Wainwright lowered its price target on HRTX to $2 from $4 while maintaining a Buy rating after the U.S. […]

The selloff highlighted the risks facing smaller companies operating in biotechnology and emerging technology.

Healthcare stocks declined late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.8% an

After Reviewing the Ruling, Heron Believes It has Substantial Grounds for Obtaining Reversal in an AppealCARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Sl

We recently compiled a list of the 10 Best Penny Stocks Under $1 According to Hedge Funds. Heron Therapeutics, Inc. (NASDAQ:HRTX) is another of the best penny stocks on this list. TheFly reported on May 11 that HRTX saw its price target reduced to $4 from $6 while the Buy rating was reiterated in a recent research […]

Heron Therapeutics Inc (HRTX) reports strong recovery and strategic expansions despite weather-related setbacks and competitive pressures.

Moby summary of Heron Therapeutics, Inc.'s Q1 2026 earnings call

Heron Therapeutics maintained its full-year outlook as growth in its Acute Care franchise helped offset ongoing weakness in oncology products during the first quarter. Key Investor TakeawaysHeron Therapeutics, Inc.